A Study of APG-3288 in Relapsed/Refractory Blood Cancers
Recruiting now · Phase 1
Conditions studied: Relapsed/Refractory Hematological Malignancies, Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia (CLL/SLL, Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL; Including Richter Transformation), Relapsed/Refractory Mantle Cell Lymphoma (MCL), Relapsed/Refractory Waldenström Macroglobulinemia (WM), Relapsed/Refractory Marginal Zone Lymphoma (MZL), Relapsed/Refractory Follicular Lymphoma (FL)
In brief
This is a Phase I, multicenter, open-label, two-stage study of APG-3288 monotherapy, aiming to determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of APG-3288 administered orally once daily in patients with relapsed/refractory (R/R) hematologic malignancies.
Key facts
- Study ID
- NCT07424833
- Run by
- Ascentage Pharma Group Inc.
- People needed
- 180
- Starts
- 2026-08-01
- Expected to finish
- 2031-12-01
- Last updated by the study team
- 2026-07-30
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- START New Jersey — East Brunswick, New Jersey, United States (enrolling)
- Henan Cancer Hospital — Zhengzhou, Henan, China (enrolling)
- START Los Angele — Los Angeles, California, United States (enrolling)
- START Midwest — Grand Rapids, Michigan, United States (enrolling)
- The University of TX MD Anderson Cancer Center — Houston, Texas, United States
- Mayo Clinic — Jacksonville, Florida, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.